SETDB1 regulates SMAD7 expression for breast cancer metastasis
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Breast cancer (BRC) is the most invasive cancer in women. Although the survival rate of BRC is gradually increasing due to improved screening systems, development of novel therapeutic targets for inhibition of BRC proliferation, metastasis and recurrence have been constantly needed. Thus, in this study, we identified overexpression of SETDB1 (SET Domain Bifurcated 1), a histone methyltransferase, in RNA-seq data of BRC derived from TCGA portal. In Gene Ontology (GO) analysis, cell migration-related GO terms were enriched, and we confirmed down-regulation of cell migration/invasion and alteration of EMT /MET markers after knockdown of SETDB1. Moreover, gene network analysis showed that SMAD7 expression is regulated by SETDB1 levels, indicating that up-regulation of SMAD7 by SETDB1 knockdown inhibited BRC metastasis. Therefore, development of SETDB1 inhibitors and functional studies may help develop more effective clinical guidelines for BRC treatment.
Abstract
Breast cancer (BRC) is the most invasive cancer in women. Although the survival rate of BRC is gradually increasing due to improved screening systems, development of novel therapeutic targets for inhibition of BRC proliferation, metastasis and recurrence have been constantly needed. Thus, in this study, we identified overexpression of SETDB1 (SET Domain Bifurcated 1), a histone methyltransferase, in RNA-seq data of BRC derived from TCGA portal. In Gene Ontology (GO) analysis, cell migration-related GO terms were enriched, and we confirmed down-regulation of cell migration/invasion and alteration of EMT /MET markers after knockdown of SETDB1. Moreover, gene network analysis showed that SMAD7 expression is regulated by SETDB1 levels, indicating that up-regulation of SMAD7 by SETDB1 knockdown inhibited BRC metastasis. Therefore, development of SETDB1 inhibitors and functional studies may help develop more effective clinical guidelines for BRC treatment.
참고문헌 (34)
- Dent R, "Triple-negative breast cancer : clinical features and patterns of recurrence", Clin Cancer Res, 13, pp.4429~4434 (2007)
- Lee A, "Triple negative breast cancer : Emerging therapeutic modalities and novel combination therapies", Cancer Treat Rev, 62, pp.110~122 (2017)
- 박재인, "BLT2, a leukotriene B4 receptor 2, as a novel prognostic biomarker of triple-negative breast cancer", BMB Reports, 51(8), pp.373~377 (2018), 생화학분자생물학회
- Kim K, "EHMT2is a metastasis regulator in breast cancer", Biochem Biophys Res Commun, 496, pp.758~762 (2018)
- Hongming Song, "MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD", BMB Reports, 51(11), pp.602~607 (2018), 생화학분자생물학회
- Schultz DC, "SETDB1 : a novel KAP-1-associated histone H3, lysine 9-specific methyltransferase that contributes to HP1-mediated silencing of euchromatic genes by KRAB zinc-finger proteins", Genes Dev, 16, pp.919~932 (2002)
- Kazanets A, "Epigenetic silencing of tumor suppressor genes : Paradigms, puzzles, and potential", Biochim Biophys Acta, 1865, pp.275~288 (2016)
- Kondo Y, "Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer", Mol Cell Biol, 23, pp.206~215 (2003)
- Han TS, "The epigenetic regulation of HCC metastasis", Int J Mol Sci, 19, pp.3978~ (2018)
- Ceol CJ, "The histone methyltransferase SETDB1 is recurrently amplified in melanoma and accelerates its onset", Nature, 471, pp.513~517 (2011)
- Chen K, "Histone Methyltransferase SETDB1 promotes the progression of colorectal cancer by inhibiting the expression of TP53", J Cancer, 8, pp.3318~3330 (2017)
- Ho YJ, "Significance of histone methyltransferase SETDB1 expression in colon adenocarcinoma", APMIS, 125, pp.985~995 (2017)
- Spyropoulou A, "Role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis : modulation of cell proliferation, migration, and colony formation", Neuromolecular Med, 16, pp.70~82 (2014)
- Wong CM, "Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis", Hepatology, 63, pp.474~487 (2016)
- Zhang H, "MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway", Stem Cells, 32, pp.2858~2868 (2014)
- Eymery A, "The methyltransferase Setdb1 is essential for meiosis and mitosis in mouse oocytes and early embryos", Development, 143, pp.2767~2779 (2016)
- Na HH, "SETDB1-mediated FosB regulation via ERK2 is associated with an increase in cell invasiveness during anticancer drug treatment of A549human lung cancer cells", Biochem Biophys Res Commun, 495, pp.512~518 (2018)
- Zhang Y, "Histone methyltransferase SETDB1 promotes cells proliferation and migration by interacting withTiam1 in hepatocellular carcinoma", BMC Cancer, 18, pp.539~ (2018)
- Miyazawa K, "Regulation of TGF-beta family signaling by inhibitory smads", Cold Spring Harb Perspect Biol, 9 (2017)
- Chen X, "Melatonin attenuates hypoxia-induced epithelial-mesenchymal transition and cell aggressive via Smad7", CCL20 in glioma, 2017, pp.8, 93580~93592
- Juarez P, "Halofuginone inhibits TGF-beta", BMP signaling and in combination with zoledronic acid enhances inhibition of breast cancer bone metastasis, 2017, pp.8, 86447~86462
- Wang H, "NR2F2 inhibits Smad7 expression and promotes TGF-beta-dependent epithelial-mesenchymal transition of CRC via transactivation of miR-21", Biochem Biophys Res Commun, 485, pp.181~188 (2017)
- Zhang Z, "Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7", Nat Commun, 8, pp.2116~ (2017)
- Sauter ER, "Breast cancer prevention : current approaches and future directions", Eur J Breast Health, 14, pp.64~71 (2018)
- Ross JS, "The HER-2", neu oncogene in breast cancer : prognostic factor, predictive factor, and target for therapy, 1998, pp.16, 413~428
- Regina C, "Setdb1, a novel interactor of DeltaNp63, is involved in breast tumorigenesis", Oncotarget, 7, pp.28836~28848 (2016)
- Comsa S, "The Story of MCF-7 Breast Cancer Cell Line : 40 years of Experience in Research", Anticancer Res, 35, pp.3147~3154 (2015)
- Gest C, "Rac3 induces a molecular pathway triggering breast cancer cell aggressiveness : differences in MDA-MB-231 and MCF-7 breast cancer cell lines", BMC Cancer, 13, pp.63~ (2013)
- Bellomo C, "Transforming growth factor beta as regulator of cancer stemness and metastasis", Br J Cancer, 115, pp.761~769 (2016)
- Kim SK, "The novel prognostic marker, EHMT2, is involved in cell proliferation via HSPD1regulation in breast cancer", Int J Oncol, 54, pp.65~76 (2019)
- Ryu JW, "Novel prognostic marker PRMT1 regulates cell growth via downregulation of CDKN1A in HCC", Oncotarget, 8, pp.115444~115455 (2017)
- Jung KB, "In vitro and in vivo imaging and tracking of intestinal organoids from human induced pluripotent stem cells", FASEB J, 32, pp.111~122 (2018)
- Kim DS, "A liver-specific gene expression panel predicts the differentiation status of in vitro hepatocyte models", Hepatology, 66, pp.1662~1674 (2017)
- Son MY, "Comparative in silico profiling of epigenetic modifiers in human tissues", Mol Biol Rep, 45, pp.309~314 (2018)